MEDIPOST is conquering incurablediseases through stem cell therapy
Since its foundation, the company has stayed on the right course in the midst of countless adversities in stem cell industry and through years of cutting-edge research, MEDIPOST has taken a dominating step in the global biomedical field by achieving market approval of the world’s first allogeneic stem cell drug – CARTISTEM®, in Korea.
Biotechnology is believed to be one of the leading industries which will provide a springboard for korea’s future economic growth. We at MEDIPOST, will continue to do our very best to overcome the current limitations of the treatment paradigm for incurable diseases and find new and innovative therapeutic solutions to meet the unmet medical needs. Our efforts and advancements in stem cell-based technologies will help excel korea’s biotechnology industry and place Korea at the front in the global industry of regenerative medicine.
MEDIPOST promises to grow into a respected company that protects precious lives by placing a high priority on human dignity and value of life. We shall always walk the path of goodness and righteousness that we can go with many people.
CEO and PresidentYang, Yoon SunMEDIPOST Co., Ltd.
A better tomorrow through True Innovation in Biotechnology
While placing the highest value on lives of people, MEDIPOST has continued to challenge itself through relentless R&D efforts centered on stem cell-based therapeutics and bring next-generation medicines to everyone.
The motif of the MEDIPOST CI is based on the structure of DNA.
DNA stores genetic information of life.
Just as many living organisms are inherited and prospered by the mother’s genetic traits, DNA in our logo delivers a visually diversified, yet consistent brand image that contains our core value.